Does olanzapine inhibit the psychomimetic effects of δ9- tetrahydrocannabinol?

Journal of Psychopharmacology

Volumn 26, Issue 10, 2012, Pages 1307-1316

  Kleinloog, Daniël ^a,b   Liem Moolenaar, Marieke ^a   Jacobs, Gabriël ^a,b   Klaassen, Erica ^a   De Kam, Marieke ^a   Hijman, Ron ^c   Van Gerven, Joop ^a,b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

biological model; clinical pharmacology; human volunteers; olanzapine; psychiatric status rating scales; psychological model; psychosis model; psychotic disorders; schizophrenia; Tetrahydrocannabinol

Indexed keywords

DIPHENHYDRAMINE; DRONABINOL; HYDROCORTISONE; OLANZAPINE; PLACEBO; PROLACTIN;

ADULT; ARTICLE; BODY EQUILIBRIUM; BODY POSTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; EYE MOVEMENT; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; PSYCHOSIS; PUPIL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; VISUAL ANALOG SCALE;

ABSORPTION; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG USERS; HALLUCINOGENS; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NETHERLANDS; NEUROTOXICITY SYNDROMES; PSYCHOTIC DISORDERS; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 84866246492     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112446534     Document Type: Article

References (40)

1. Agid O, Mamo D, Ginovart N, et al. Striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology. 2007 ; 32 (6). 1209-1215
2. Barkus E, Morrison PD, Vuletic D, et al. Does intravenous δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol. 2011 ; 25: 1462-1468
3. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010 ; 35 (3). 764-774
4. BlewettDBChwelosN (1959) Handbook for the therapeutic use of lysergic acid diethylamide-25. Individual and group procedures. Available at: www.maps.org/ritesofpassage/lsdhandbook.html.
5. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974 ; 47 (3). 211-218
6. Bossong MG, Van Berckel BN, Boellaard R, et al. Delta 9- tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology. 2009 ; 34 (3). 759-766
7. Bowdle TA, Radant AD, Cowly DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998 ; 88 (1). 82-88
8. Crippa JE, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009 ; 24 (7). 515-523
9. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005 ; 57 (6). 594-608
10. D'Souza DC, Braley G, Blaise R, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2008a ; 198 (4). 587-603
11. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004 ; 29 (8). 1558-1572
12. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008b ; 33 (10). 2505-2516
13. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009 ; 259 (7). 413-431
14. Dalton VS, Long LE, Weickert CS, Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology. 2011 ; 36 (8). 1620-1630
15. de Visser SJ, Van der Post J, Pieters MS, Cohen AF, Van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001 ; 51 (2). 119-132
16. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004 ; 29 (11). 2108-2114
17. Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol. 2011 ; 164 (4). 1162-1194
18. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998 ; 155 (7). 921-928
19. Kassahun K, Mattiuz E, Nyhart E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997 ; 25 (5). 573-583
20. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13 (2). 261-276
21. Kelly DL, Gorelick DA, Conley RR, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2011 ; 31 (1). 86-91
22. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994 ; 51 (3). 199-214
23. Laeng B, Låg T, Brennen T. Reduced Stroop interference for opponent colors may be due to input factors: evidence from individual differences and a neural network simulation. J Exp Psychol Hum Percept Perform. 2005 ; 31 (3). 438-452
24. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999 ; 10 (8). 1665-1669
25. Liem-Moolenaar M, Gray FA, de Visser SJ, et al. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol. 2010a ; 24 (1). 73-82
26. Liem-Moolenaar M, Te Beek ET, De Kam ML, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010b ; 24 (11). 1697-1708
27. McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy. 2010 ; 21: 10-19
28. Morrens M, Wezenberg E, Verkes RJ, Hulstijn W, Ruigt GS, Sabbe BG. Psychomotor and memory effects of haloperidol, olanzapine and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol. 2007 ; 27 (1). 15-21
29. Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009 ; 39 (10). 1607-1616
30. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010 ; 13 (10). 1161-1169
31. Schmitt JA, Jorissen BL, Sobczak S, et al. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol. 2000 ; 14 (1). 21-29
32. Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. Behavioral, cognitive and pathophysiological effects of cannabinoids: relevance to psychosis and schizophrenia. Rev Bras Psiquiatr. 2010 ; 32 (S1). 15-30
33. Stokes PR, Egerton A, Watson B, et al. Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. NeuroImage. 2010 ; 52 (4). 1521-1527
34. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum?. Neuroimage. 2009 ; 48 (1). 186-190
35. Strakowski SM, Sax KW, Setters MJ, Keck PE. Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry. 1996 ; 40 (9). 872-880
36. Twa MD, Bailey MD, Hayes J, Bullimore M. Estimation of pupil size by digital photography. J Cataract Refract Surg. 2004 ; 30 (2). 381-389
37. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effect of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther. 1991 ; 50 (2). 172-180
38. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 ; 9 (17). 3897-3902
39. Wong DF, Kuwabara H, Horti AG, et al. Quantification of cerebral cannabinoid receptor subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 2010 ; 52 (4). 1505-1513
40. Zuurman L, Roy C, Schoemaker RC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008 ; 22 (7). 707-716